What are the interactions of verapamil with P‑glycoprotein (P‑gp) and CYP2D6, and how does verapamil affect the QT interval and cardiac conduction?

Verapamil Drug Interactions and Cardiac Effects

Verapamil is a moderate CYP3A4 inhibitor and also inhibits P-glycoprotein, but is NOT significantly metabolized by CYP2D6; it slows AV nodal conduction and can prolong the PR interval, but does NOT typically prolong the QT interval—in fact, it may shorten QT in certain conditions. 1

P-glycoprotein (P-gp) Interactions

Verapamil is a potent P-glycoprotein inhibitor, which creates clinically significant drug interactions by increasing plasma concentrations of P-gp substrates 1, 2. This mechanism is responsible for:

• Increased digoxin levels: Monitor digoxin concentrations when coadministered with verapamil 1
• Elevated direct oral anticoagulant (DOAC) levels: Particularly problematic with dabigatran, where verapamil increases bleeding risk by 43-52% compared to non-P-gp inhibiting alternatives 3
• Enhanced exposure to other P-gp substrates including: dabigatran, edoxaban, rivaroxaban, topotecan, trabectedin, vincristine, and colchicine 1, 4

The P-gp inhibition by verapamil is mediated not only by the parent compound but also by its metabolite norverapamil and D-703, while other metabolites (D-617 and D-620) are actually P-gp substrates rather than inhibitors 5. This creates complex, concentration-dependent interactions where verapamil can cause non-competitive inhibition at lower concentrations and competitive inhibition at higher concentrations 6.

CYP450 Interactions

Verapamil is a moderate CYP3A4 inhibitor but is NOT a CYP2D6 inhibitor or substrate 1, 2. The CYP3A4 inhibition leads to:

• Contraindication with dofetilide due to increased dofetilide levels and torsades de pointes risk 1, 4
• Increased statin exposure: Particularly with simvastatin and lovastatin (doses should not exceed 10-20 mg daily when combined with verapamil) 2
• Drug interactions requiring monitoring: itraconazole, bosutinib, ceritinib, cilostazol, cyclosporine, everolimus, ibrutinib, ivabradine, ranolazine, simeprevir, and grapefruit juice 1, 4

Verapamil itself undergoes extensive CYP3A4-mediated metabolism with less than 5% excreted unchanged 7, 5. The major metabolite norverapamil reaches plasma concentrations equal to verapamil and has approximately 20% of verapamil's cardiovascular activity 7.

Effects on QT Interval

Verapamil does NOT prolong the QT interval under typical clinical conditions—this is a critical distinction from many other antiarrhythmic agents 1. In fact:

• Verapamil can shorten the QT interval in models of acquired long QT syndrome by preferentially abbreviating action potential duration in epicardial cells more than in midmyocardial cells, thereby reducing transmural dispersion of repolarization 8
• In experimental models mimicking KCNQ1 defects (acquired LQTS), verapamil dose-dependently decreased QT interval, suppressed early afterdepolarizations, and prevented torsades de pointes 8
• One case report documented QTc prolongation (583 msec) with combined high-dose verapamil (480 mg/day) and erythromycin, but this was attributed to complete AV block causing bradycardia (a known QT-prolonging condition) rather than direct QT prolongation by verapamil 9

The lack of QT prolongation distinguishes verapamil from Class IA and Class III antiarrhythmics, making it safer in patients at risk for torsades de pointes.

Effects on Cardiac Conduction

Verapamil significantly slows AV nodal conduction and can cause bradyarrhythmias 1, 10, 1, 10, 7:

AV Nodal Effects:

• Prolongs PR interval in a concentration-dependent manner, especially during early titration 7
• First-degree AV block occurs commonly and is often asymptomatic 7
• Higher-degree AV block (second- or third-degree) occurs infrequently (0.8%) but requires dose reduction or discontinuation 7
• Contraindicated in patients with AV block greater than first degree or SA node dysfunction without a pacemaker 1, 4, 7

Sinus Node Effects:

• Can interfere with sinus node impulse generation in patients with sick sinus syndrome 7
• May induce sinus arrest or sinoatrial block 7
• Normal sinus rhythm is usually not affected in patients without underlying conduction disease 7

Critical Drug Combination Warnings:

• Avoid combining with beta-blockers in patients with ventricular dysfunction or heart failure due to additive negative inotropic and chronotropic effects 11, 12, 7, 13
• One fatal case report documented heart failure after verapamil-metoprolol combination, potentially enhanced by CYP2D6 poor metabolizer status affecting metoprolol levels (not verapamil) 13
• The combination of verapamil with beta-blockers can cause excessive bradycardia, AV block, and worsening heart failure 11, 14, 7
• Do NOT use serially with other AV nodal blocking agents due to overlapping effects and risk of profound bradycardia 10

Accessory Pathway Considerations:

• Contraindicated in Wolff-Parkinson-White (WPW) syndrome with atrial fibrillation/flutter because verapamil may shorten the antegrade effective refractory period of the accessory pathway, potentially causing acceleration of ventricular rate or ventricular fibrillation 1, 4, 7

Common Pitfalls to Avoid

1. Do NOT assume verapamil prolongs QT—it does not, unlike many antiarrhythmics
2. Do NOT combine with beta-blockers in patients with heart failure or significant ventricular dysfunction
3. Always reduce digoxin dose by 30-50% when adding verapamil and monitor levels 1
4. Avoid dabigatran with verapamil even in normal renal function due to 43-52% increased bleeding risk 3
5. Limit simvastatin to ≤10 mg daily and lovastatin to ≤20 mg daily when combined with verapamil 2
6. Screen for WPW before using verapamil in atrial fibrillation/flutter patients 1, 7